07.20.18
Headquarters: Ingelheim, Germany
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 50,000
Year Established: 1817
Pharma Revenues: $15,930 (+5%)
LOSS: $235 (-112%)
R&D: $3,687 (-1%)
TOP SELLING DRUGS
Boehringer spent much of the year working to get at the forefront of immuno-oncology research. 2017 brought great progress within external partnerships, with agreements in place investigating both cancer cell-directed therapies and immune cell-directed therapies. In a collaboration with UCLA’s Technology Development Group, Boehringer aims to develop a promising vaccine technology platform based on using the protein shell of a plant virus to deliver a self-replicating RNA vaccine cargo to cancer patients’ antigen-presenting cells, which in turn would direct the immune system to eliminate the cancer.
Another immuno-oncology partnership with Siama Therapeutics is trying to identify anti-cancer therapeutics that target tumor associated carbohydrate antigens (TACAs), which are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric and breast. A third cancer-focused collaboration with AbeXXa Biologics aims to identify a new series of selective molecular targets for cancer from the many thousands of proteins found on the interior of a tumor cell. AbeXXa has received funding through the Boehringer Ingelheim Venture Fund for this research. In addition, Boehringer and Vanderbilt University expanded their already successful existing collaboration to develop novel anti-cancer compounds.
Boehringer is on the rise in the digital space as well, building Digital Lab “BI X” with focus on innovative digital solutions in healthcare. The start-up came after a €10 million investment, and will work with multiple business units including Biopharmaceuticals and Human Pharma within the company to develop prototypes for new products and solutions, and then test them together in pilot phases. In November 2017, Boehringer also launched a second digital platform, opnMe.com. The platform offers free and open access to selected preclinical molecules for non-clinical investigation to scientists worldwide. The goal is to create possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.
In other news, Boehringer announced a €230 million investment into a new Biologics Development Center at the company’s R&D site in Biberach, Germany. The center bundles biologics development, increases capacity, and expands the clinical supply network. The facility will launch in 2020, and will employ more than 500 staff.
twitter.com/Boehringer
www.boehringer-ingelheim.com
Headcount: 50,000
Year Established: 1817
Pharma Revenues: $15,930 (+5%)
LOSS: $235 (-112%)
R&D: $3,687 (-1%)
TOP SELLING DRUGS
Drug | Indication | 2017 Sales | (+/-%) |
Spiriva | COPD, asthma | $3,385 | -6% |
Pradaxa | atrial fibrillation | $1,723 | 4% |
Trajenta | type 2 diabetes | $1,597 | 18% |
Jardiance | type 2 diabetes | $1,207 | 133% |
Boehringer spent much of the year working to get at the forefront of immuno-oncology research. 2017 brought great progress within external partnerships, with agreements in place investigating both cancer cell-directed therapies and immune cell-directed therapies. In a collaboration with UCLA’s Technology Development Group, Boehringer aims to develop a promising vaccine technology platform based on using the protein shell of a plant virus to deliver a self-replicating RNA vaccine cargo to cancer patients’ antigen-presenting cells, which in turn would direct the immune system to eliminate the cancer.
Another immuno-oncology partnership with Siama Therapeutics is trying to identify anti-cancer therapeutics that target tumor associated carbohydrate antigens (TACAs), which are present in the majority of solid tumors including ovarian, pancreatic, prostate, colon, gastric and breast. A third cancer-focused collaboration with AbeXXa Biologics aims to identify a new series of selective molecular targets for cancer from the many thousands of proteins found on the interior of a tumor cell. AbeXXa has received funding through the Boehringer Ingelheim Venture Fund for this research. In addition, Boehringer and Vanderbilt University expanded their already successful existing collaboration to develop novel anti-cancer compounds.
Boehringer is on the rise in the digital space as well, building Digital Lab “BI X” with focus on innovative digital solutions in healthcare. The start-up came after a €10 million investment, and will work with multiple business units including Biopharmaceuticals and Human Pharma within the company to develop prototypes for new products and solutions, and then test them together in pilot phases. In November 2017, Boehringer also launched a second digital platform, opnMe.com. The platform offers free and open access to selected preclinical molecules for non-clinical investigation to scientists worldwide. The goal is to create possibilities for further independent and collaborative discovery as well as the identification of novel treatment approaches for patients.
In other news, Boehringer announced a €230 million investment into a new Biologics Development Center at the company’s R&D site in Biberach, Germany. The center bundles biologics development, increases capacity, and expands the clinical supply network. The facility will launch in 2020, and will employ more than 500 staff.